IP Verse

Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist - EP3703818B1

PatentPatent Analysis

EP3703818

REGENERON PHARMACEUTICALS
Application Number
EP18799655A
Filing Date
Oct 29, 2018
Status
Granted And Under Opposition
Sep 29, 2023
Grant Date
Nov 1, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3506931B1
EP3889181B1

Bibliography

The patent EP3703818B1 was granted to Regeneron Pharmaceuticals on Nov 1, 2023 following the initial filing on Oct 29, 2018 under the application number EP18799655A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR H ULRICH DORRIESAug 1, 2024ADMISSIBLE
LUIGIAug 1, 2024ADMISSIBLE
MICHALSKI HUTTERAMNN & PARTNER PATENTANWALTE MBBAug 1, 2024ADMISSIBLE
HAMPTON KNOWLESJul 31, 2024ADMISSIBLE
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBJul 30, 2024ADMISSIBLE
BOULT WADE TENNANTJul 30, 2024ADMISSIBLE
LANYON OPPOSITIONSJul 30, 2024ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents